

SEQUENCE LISTING

<110> Ablevia biotech GmbH

<120> Compound for the sequestration of undesirable antibodies in a patient

<130> R 76166

<150> EP 19164784.1

<151> 2019-03-23

<160> 23

<170> BiSSAP 1.3.6

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 1

Leu	Lys	Trp	Asn	Pro	Asp	Asp	Tyr	Gly	Gly	Val	Lys	Lys	Ile	His	Ile
1				5				10					15		
Pro	Ser	Glu	Lys												
			20												

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 2

Trp	Asn	Pro	Asp	Asp	Tyr	Gly	Gly	Val	Lys
1			5					10	

<210> 3

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 3

Val Lys Lys Ile His Ile Pro Ser Glu Lys
1 5 10

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 4

Val Lys Lys Ile His Ile Pro Ser Glu Lys Gly
1 5 10

<210> 5

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 5

Arg Pro Gln Lys Arg Pro Ser Cys Ile Gly Cys Lys Gly Thr His
1 5 10 15

<210> 6

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 6

Arg Pro Gln Lys Arg Pro Ser Cys Ile Gly Cys Lys Gly Ala His
1 5 10 15

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 7

Lys Arg Pro Ser Cys Ile Gly Cys Lys

1 5

<210> 8

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 8

Met Ile Leu Asn Ser Ser Thr Glu Asp Gly Ile Lys Arg Ile Gln Asp

1 5 10 15

Asp Cys Pro Lys Ala Gly Arg His Asn Tyr Ile

20 25

<210> 9

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 9

Thr Ala Met Glu Tyr Arg Trp Pro Phe Gly Asn Tyr Leu Cys Lys

1 5 10 15

<210> 10

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 10

Ala Ile Ile His Arg Asn Val Phe Phe Ile Glu Asn Thr Asn Ile Thr

1 5 10 15

Val Cys Ala Phe His Tyr Glu Ser Gln Asn Ser Thr Leu Pro

20 25 30

<210> 11
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 11
Asp Val Leu Ile Gln Leu Gly Ile Ile Arg Asp Cys Arg
1 5 10

<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 12
Ala Phe His Tyr Glu Ser Gln
1 5

<210> 13
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 13
Gly Arg Pro Gln Lys Arg Pro Ser Cys Ile Gly
1 5 10

<210> 14
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 14

Cys Gly Arg Pro Gln Lys Arg Pro Ser Cys Ile Gly Cys Lys Gly
1 5 10 15

<210> 15

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 15

Leu Lys Trp Asn Pro Asp Asp Tyr Gly Gly Val Lys Lys Ile His Ile
1 5 10 15
Pro Ser Glu Lys Gly Cys
20

<210> 16

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 16

Asp His Thr Leu Tyr Thr Pro Tyr His Thr His Pro Gly
1 5 10

<210> 17

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 17

Gly Gly Val Lys Lys Ile His Ile Pro Ser Glu Lys
1 5 10

<210> 18

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Seq_18

<400> 18

Leu Gln Gln Gln Asn Thr

1 5

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Seq_19

<400> 19

Thr Thr Thr Gly Gln Asn Asn Asn Ser

1 5

<210> 20

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Seq_20

<400> 20

Gly Thr Ala Asn Thr Gln

1 5

<210> 21

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Seq_21

<400> 21

Ile Pro Asn Pro Leu Leu Gly Leu Asp Cys

1 5 10

<210> 22

<211> 23

<212> PRT

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Seq_22

<400> 22

Ile Pro Asn Pro Leu Leu Gly Leu Asp Gly Gly Ser Gly Asp Tyr Lys
1 5 10 15
Asp Asp Asp Asp Lys Gly Lys
20

<210> 23

<211> 24

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> Seq_23

<400> 23

Val Lys Lys Ile His Ile Pro Ser Glu Lys Gly Gly Ser Gly Asp Tyr
1 5 10 15
Lys Asp Asp Asp Asp Lys Gly Lys
20